Kangmei Pharma | 600518 - Selling And Administration Expenses


Kangmei Pharma reported CNY274.41M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
Avita Medical AUD 20.98M 253K Jun/2025
Cspc Pharmaceutical CNY 1.97B 404.66M Sep/2025
Dianthus Therapeutics USD 8.2M 669K Sep/2025
Genomma Lab Internacional MXN 1.93B 35.32M Sep/2025
Hypermarcas BRL 687.46M 23.62M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
IQVIA Holdings USD 468M 46M Dec/2025
Jiangsu Hengrui CNY 3.23B 111.82M Sep/2025
Kangmei Pharma CNY 274.41M 15.05M Sep/2025
Moderna USD 308M 40M Dec/2025
Organon & Co USD 399M 54M Sep/2025
Revvity USD 251.73M 9.82M Dec/2025
Sh Fosun Pharma CNY 3.12B 22.02M Sep/2025
Tectonic Therapeutic USD 4.96M 190K Sep/2025
Viatris USD 886.6M 42.1M Sep/2025
Wuxi Apptec CNY 778.61M 34.33M Sep/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025
Zz Pientze Pharmaceu CNY 171.91M 343.2M Sep/2025